The Europe PARP Inhibitor Biomarkers Market would witness market growth of 8.1% CAGR during the forecast period (2024-2031).
The Germany market dominated the Europe PARP Inhibitor Biomarkers Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $92 Million by 2031. The UK market is exhibiting a CAGR of 7.1% during (2024 - 2031). Additionally, The France market would experience a CAGR of 8.9% during (2024 - 2031).
The rising incidence of various cancer types, including breast, ovarian, prostate, and pancreatic cancer, is driving the demand for effective treatment options. PARP inhibitors have shown promising results in clinical trials and have been approved to treat certain cancers.
Moreover, the applications of it are multifaceted, encompassing various aspects of oncology care and precision medicine. For example, one of the primary applications of this is patient selection for this therapy.
The increasing prevalence of cancer in Europe contributes to the expansion of precision oncology practices, which focus on tailoring treatments to individual patients based on their molecular characteristics. these are crucial in guiding treatment decisions by identifying patients with specific DNA repair deficiencies likely to respond to its therapy.
Based on Product, the market is segmented into Kits, and Assays. Based on Application, the market is segmented into Breast Cancer, Ovarian Cancer, and Others. Based on Services, the market is segmented into BRCA 1 & 2 Testing, HRD Testing, HRR Testing, and Others.Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The Germany market dominated the Europe PARP Inhibitor Biomarkers Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $92 Million by 2031. The UK market is exhibiting a CAGR of 7.1% during (2024 - 2031). Additionally, The France market would experience a CAGR of 8.9% during (2024 - 2031).
The rising incidence of various cancer types, including breast, ovarian, prostate, and pancreatic cancer, is driving the demand for effective treatment options. PARP inhibitors have shown promising results in clinical trials and have been approved to treat certain cancers.
Moreover, the applications of it are multifaceted, encompassing various aspects of oncology care and precision medicine. For example, one of the primary applications of this is patient selection for this therapy.
The increasing prevalence of cancer in Europe contributes to the expansion of precision oncology practices, which focus on tailoring treatments to individual patients based on their molecular characteristics. these are crucial in guiding treatment decisions by identifying patients with specific DNA repair deficiencies likely to respond to its therapy.
Based on Product, the market is segmented into Kits, and Assays. Based on Application, the market is segmented into Breast Cancer, Ovarian Cancer, and Others. Based on Services, the market is segmented into BRCA 1 & 2 Testing, HRD Testing, HRR Testing, and Others.Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
List of Key Companies Profiled
- Myriad Genetics, Inc.
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- NeoGenomics Laboratories
- Qiagen N.V
- Agilent Technologies, Inc.
- Merck KGaA
- Bayer AG
- AstraZeneca PLC
- GlaxoSmithKline PLC (GSK)
Market Report Segmentation
By Product- Kits
- Assays
- Breast Cancer
- Ovarian Cancer
- Others
- BRCA 1 & 2 Testing
- HRD Testing
- HRR Testing
- Others
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Europe PARP Inhibitor Biomarkers Market by Product
Chapter 5. Europe PARP Inhibitor Biomarkers Market by Application
Chapter 6. Europe PARP Inhibitor Biomarkers Market by Services
Chapter 7. Europe PARP Inhibitor Biomarkers Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Myriad Genetics, Inc.
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- NeoGenomics Laboratories
- Qiagen N.V
- Agilent Technologies, Inc.
- Merck KGaA
- Bayer AG
- AstraZeneca PLC
- GlaxoSmithKline PLC (GSK)
Methodology
LOADING...
